Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery
Sponsor : Undisclosed
Deal Size : $300.0 million
Deal Type : Collaboration
GenKOre Announces Collaboration with a US-based Company on In vivo Gene-editing Therapy
Details : The collaboration will utilize GenKOre's proprietary CRISPR-Cas platform, TaRGET. The TaRGET platform is distinct from the most popular genome editing technology, CRISPR-Cas9, in that the whole editing module can be delivered with a single AAV vector.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 26, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery
Sponsor : Undisclosed
Deal Size : $300.0 million
Deal Type : Collaboration